• Sriraag Balaji Srinivasan, Amro Sehly, Biyanka Jaltotage, Simon Qin, Abdul Rahman Ihdayhid, James Marangou, James M Rankin, Frank M Sanfilippo, and Girish Dwivedi.
• Department of Cardiology, Fiona Stanley Hospital, Perth, WA, Australia.
• Ir J Med Sci. 2023 Aug 1; 192 (4): 164516471645-1647.

BackgroundOptimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) remains controversial.AimWe investigated the relationship between DAPT duration following PCI and long-term ischemic and bleeding outcomes under real-world conditions.MethodsPatients aged ≥ 65 years who underwent PCI with stenting in Western Australian hospitals between 2003 and 2008 and survived 2 years were identified from linked hospital admissions data. The primary outcome was major adverse cardiovascular and cerebrovascular events (MACCE) defined as a composite of all-cause death and admissions for acute coronary syndrome (ACS), coronary artery revascularization procedure, stroke, and major bleeding. Secondary outcomes were ACS admissions, all-cause death, and major bleeding admissions. Patients were followed up for 5 years from initial PCI.ResultsA total of 3963 patients were included in the final analysis. The mean age of the cohort was 74.5 ± 6.1 years with 67.3% males. No significant difference was seen with 6-12, 12-18, or 18-24 months DAPT, compared to 0-6 months DAPT duration for MACCE and all secondary outcomes at 3- and 5-year post-PCI.ConclusionThere is no significant difference in both bleeding and ischemic outcomes in long-term DAPT as compared to short-term DAPT for first- and second-generation drug-eluting stents in a real-world population.© 2022. The Author(s).

21 keywords...

hide…